| Market Cap | 734.22M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | 5.26M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -5.00% |
| Sales | 103.23M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
| Dividend | N/A | Price/Book | 11.54 | EPS next 5Y | - | 52W High Chg | -41.00% |
| Recommedations | - | Quick Ratio | 2.87 | Shares Outstanding | 690.69M | 52W Low Chg | 17.00% |
| Insider Own | 11.11% | ROA | 0.56% | Shares Float | 600.56M | Beta | 1.67 |
| Inst Own | 18.58% | ROE | 7.65% | Shares Shorted/Prior | -/- | Price | 1.05 |
| Gross Margin | 84.11% | Profit Margin | 5.10% | Avg. Volume | 403 | Target Price | - |
| Oper. Margin | 1.83% | Earnings Date | Aug 22 | Volume | 10,000 | Change | 0.00% |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.